S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals Stock Forecast, Price & News

$0.30
-0.01 (-3.20%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.29
$0.33
50-Day Range
N/A
52-Week Range
$0.29
$1.79
Volume
994,370 shs
Average Volume
661,730 shs
Market Capitalization
$13.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.47
30 days | 90 days | 365 days | Advanced Chart
Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


NovaBay Pharmaceuticals logo

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc. engages in development of products for eye care. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Headlines

NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks
January 20, 2022 |  finance.yahoo.com
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
November 18, 2021 |  finance.yahoo.com
NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:NBY
Employees
24
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.93 million
Book Value
$0.29 per share

Profitability

Net Income
$-11.03 million
Pretax Margin
-96.71%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,134,000
Market Cap
$13.60 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
1/23/2022
Next Earnings (Estimated)
3/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.06 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

Is NovaBay Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NovaBay Pharmaceuticals stock.
View analyst ratings for NovaBay Pharmaceuticals
or view top-rated stocks.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a decrease in short interest in December. As of December 31st, there was short interest totaling 1,660,000 shares, a decrease of 20.2% from the December 15th total of 2,080,000 shares. Based on an average daily volume of 923,600 shares, the short-interest ratio is presently 1.8 days. Approximately 4.7% of the company's stock are sold short.
View NovaBay Pharmaceuticals' Short Interest
.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for NovaBay Pharmaceuticals
.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) released its quarterly earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 96.77% and a negative trailing twelve-month return on equity of 67.65%.
View NovaBay Pharmaceuticals' earnings history
.

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals shares reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for NBY?

1 equities research analysts have issued 12-month price targets for NovaBay Pharmaceuticals' stock. Their forecasts range from $2.20 to $2.20. On average, they anticipate NovaBay Pharmaceuticals' share price to reach $2.20 in the next twelve months. This suggests a possible upside of 626.8% from the stock's current price.
View analysts' price targets for NovaBay Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the following people:
  • Justin M. Hall, President, CEO, Director & General Counsel
  • Andrew Jones, Chief Financial Officer & Treasurer

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.30.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals has a market capitalization of $13.60 million and generates $9.93 million in revenue each year. The biopharmaceutical company earns $-11.03 million in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does NovaBay Pharmaceuticals have?

NovaBay Pharmaceuticals employs 24 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is novabay.com.

Where are NovaBay Pharmaceuticals' headquarters?

NovaBay Pharmaceuticals is headquartered at 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at (510) 899-8800, via email at [email protected], or via fax at 510-474-1577.


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.